• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    4/4/25 8:00:00 AM ET
    $ENGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ENGN alert in real time by email

    enGene Holdings Inc. (NASDAQ:ENGN, "enGene" or the "Company")), a clinical-stage, non-viral genetic medicines company, today reported the grant of inducement equity awards to seven newly-hired employees, with a grant date of April 2, 2025. The inducement awards consist of a non-qualified stock options to purchase an aggregate 144,650 of the Company's common shares. The options each have an exercise price of $4.44 per share, which is equal to the closing price of the Company's common shares on April 2, 2025, the date of grant. Each stock option has a 10-year term and will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the employee's employment commencement date and the remainder vesting in equal amounts monthly for three years thereafter, subject to the employee's continued service as an employee of, or other service provider to, the Company through the applicable vesting dates.

    The stock options were granted by the Company's independent Compensation Committee of the Board of Directors as an inducement material to each new employee entering into employment with the Company in accordance with NASDAQ Listing Rule 5635(c)(4). While the stock options were granted outside of the Amended and Restated enGene Holdings Inc. 2023 Incentive Equity Plan ("Plan"), each option will have terms and conditions consistent with those set forth under the Plan.

    About enGene

    enGene is a clinical-stage biotechnology company mainstreaming genetic medicines through the delivery of therapeutics to mucosal tissues and other organs, with the goal of creating new ways to address diseases with high clinical needs. enGene's lead program is detalimogene voraplasmid (also known as detalimogene, and previously EG-70) for patients with Non-Muscle Invasive Bladder Cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase 2 study, which includes a pivotal cohort studying detalimogene in Bacillus Calmette-Guérin (BCG)-unresponsive patients with carcinoma in situ (CIS). Detalimogene was developed using enGene's proprietary Dually Derivatized Oligochitosan (DDX) platform, which enables penetration of mucosal tissues and delivery of a wide range of sizes and types of cargo, including DNA and various forms of RNA.

    To learn more, please visit enGene.com and follow us on LinkedIn, X and BlueSky.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250404691671/en/

    For media contact:

    [email protected]



    For investor contact:

    [email protected]

    Get the next $ENGN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ENGN

    DatePrice TargetRatingAnalyst
    2/18/2025$26.00Overweight
    Piper Sandler
    2/14/2025$34.00 → $7.00Buy → Neutral
    UBS
    12/23/2024$25.00Buy
    H.C. Wainwright
    11/27/2024$23.00Outperform
    Raymond James
    11/18/2024$18.00Mkt Outperform
    JMP Securities
    8/28/2024$30.00Outperform
    Oppenheimer
    4/22/2024$30.00Overweight
    Wells Fargo
    4/15/2024$34.00Buy
    Guggenheim
    More analyst ratings

    $ENGN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Forbion Growth Opportunities Fund I Cooperatief U.A. bought $4,999,993 worth of shares (561,797 units at $8.90) (SEC Form 4)

      4 - enGene Holdings Inc. (0001980845) (Issuer)

      11/1/24 4:15:08 PM ET
      $ENGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Large owner Forbion Growth Opportunities Fund I Cooperatief U.A. bought $3,012,674 worth of shares (470,633 units at $6.40) (SEC Form 4)

      4 - enGene Holdings Inc. (0001980845) (Issuer)

      10/18/24 4:15:05 PM ET
      $ENGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Executive Officer Cooper Ronald Harold Wilfred bought $57,000 worth of shares (10,000 units at $5.70) (SEC Form 4)

      4 - enGene Holdings Inc. (0001980845) (Issuer)

      10/1/24 8:02:44 AM ET
      $ENGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ENGN
    Leadership Updates

    Live Leadership Updates

    See more
    • enGene Names Amy Pott as Chief Global Commercialization Officer

      enGene Holdings Inc. (NASDAQ:ENGN), a clinical-stage, non-viral genetic medicines company, today announced the appointment of Amy Pott as Chief Global Commercialization Officer. In this role, Ms. Pott will serve as the Company's first dedicated executive for commercialization planning and execution, reporting to enGene's Chief Executive Officer, Ron Cooper. This appointment marks a significant milestone, as the Company expects to file a Biologics License Application (BLA) with the FDA in mid-2026 for detalimogene voraplasmid, its lead investigational agent in Bacillus Calmette-Guérin (BCG)-unresponsive, non-muscle invasive bladder cancer (NMIBC), following the completion of the pivotal co

      5/28/25 7:30:00 AM ET
      $ENGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • enGene Appoints Joan Connolly as Chief Technology Officer and Anthony Cheung, Ph.D., as Chief Scientific Officer

      enGene Holdings Inc. (NASDAQ:ENGN), a clinical-stage genetic medicines company whose non-viral lead investigational product detalimogene voraplasmid (also known as detalimogene, and previously EG-70) is in an ongoing pivotal study in patients with high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (Cis), today announced the appointment of Joan Connolly as Chief Technology Officer (CTO) and member of the corporate leadership team. In addition, enGene Co-Founder and former CTO, Anthony Cheung, Ph.D., will transition to the role of Chief Scientific Officer, succeeding James Sullivan, MSc, Ph.D. Ms. Connolly's career spans

      10/21/24 8:45:00 AM ET
      $ENGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • enGene Announces Appointment of Ron Cooper as Chief Executive Officer

      Ron Cooper succeeds Jason Hanson as Chief Executive Officer and Director Company also announces Dr. Raj Pruthi's promotion to Chief Medical Officer enGene Holdings Inc. (NASDAQ:ENGN, "enGene" or the "Company"))), a clinical-stage genetic medicines company whose non-viral, intravesical lead product candidate, EG-70, is in a pivotal study for BCG-unresponsive high-risk Non-Muscle Invasive Bladder Cancer (NMIBC), today announced that Ron Cooper has joined the Company as Chief Executive Officer and member of the Board of Directors, effective July 22, 2024. This transition follows a previously announced succession plan for Jason Hanson, who will remain in service to the Company as a strategi

      7/24/24 6:30:00 AM ET
      $ENGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ENGN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Piper Sandler initiated coverage on enGene Holdings with a new price target

      Piper Sandler initiated coverage of enGene Holdings with a rating of Overweight and set a new price target of $26.00

      2/18/25 7:08:31 AM ET
      $ENGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • enGene Holdings downgraded by UBS with a new price target

      UBS downgraded enGene Holdings from Buy to Neutral and set a new price target of $7.00 from $34.00 previously

      2/14/25 8:16:16 AM ET
      $ENGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • H.C. Wainwright initiated coverage on enGene Holdings with a new price target

      H.C. Wainwright initiated coverage of enGene Holdings with a rating of Buy and set a new price target of $25.00

      12/23/24 7:22:45 AM ET
      $ENGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ENGN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Zoth Lota S.

      4 - enGene Holdings Inc. (0001980845) (Issuer)

      6/16/25 6:40:38 PM ET
      $ENGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Chief Global Comm. Ofc. Pott Amy

      4 - enGene Holdings Inc. (0001980845) (Issuer)

      6/16/25 6:40:07 PM ET
      $ENGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Joustra Wouter

      4 - enGene Holdings Inc. (0001980845) (Issuer)

      6/16/25 6:39:30 PM ET
      $ENGN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care